MedPath

Comparison between mothers at high or low risk of uterine bleeding, with regards to the effective dose of oxytocin during cesarean surgery

Not Applicable
Conditions
Health Condition 1: O721- Other immediate postpartum hemorrhage
Registration Number
CTRI/2019/11/021901
Lead Sponsor
niversity College of Mediacl Sciences and GTb Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Closed to Recruitment of Participants
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

>18 years, and posted for cesarean section will be evaluated for inclusion.

Those with � 1 risk factor for uterine atony will be included into group H (i.e., high risk group), and with lack of any such factor into group L (i.e., low risk group). The various high-risk factors for uterine atony will include multiple gestation, polyhydramnios, macrosomia, uterine fibroid, previous uterine surgery, abnormal placentation, history of previous uterine atony or PPH, high parity (� 5 previous delivery), chorioamnionitis (fever and on antibiotics for same), magnesium sulfate therapy, or need for general anesthesia.

Exclusion Criteria

Exclusion criteria will include patient refusal, active labor ( >3 cm cervical dilation), use of prior oxytocin for labor induction and/or augmentation, pre-eclampsia without magnesium sulfate therapy and absence of any pre-defined high-risk for uterine atony, coagulopathy (thrombocytopenia with platelet count <50,000/mm3 or INR >1.5), as well as history of bleeding disorder or heart disease.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
terine tone (adequate or inadequate)Timepoint: 3 minutes after bolus dose of oxytocin
Secondary Outcome Measures
NameTimeMethod
Side effects that can be attributed to the initial bolus of oxytocin including hypotension, tachycardia (10 bpm), chest pain, flushing, nausea or vomiting, and ST-T changes.Timepoint: Will be noted for upto 5 minutes after the bolus, but prior to any other uterotonic administration including rescue boluses.
© Copyright 2025. All Rights Reserved by MedPath